US 2022/0016126 A1Published application

Pde5 inhibitor powder formulations and methods relating thereto

AssigneeRespira Therapeutics, Inc.

InventorsZhen Xu, Hugh Smyth, Aileen Gibbons, Revati Shreeniwas, Pravin Soni, Dan Deaton, James Hannon, Stephen Lermer, Robert Curtis, Martin J. Donovan

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

Claims24

Dependent claims

A powder pharmaceutical composition comprising:

a) a PDE5 inhibitor or a pharmaceutically acceptable salt or ester thereof,
b) a first fraction of fine lactose particles, and
c) a second fraction of lactose particles having an average diameter of about 5 μm to about 90 μm;
wherein the PDE5 inhibitor or salt or ester thereof is present in an amount of up to about 20% by weight relative to the total weight of the overall pharmaceutical composition;
and
wherein the first fraction of fine lactose particles is present in an amount of up to about 10% by weight relative to the total weight of the lactose in the composition.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/211,071Filed 24 Mar 2021
Priority: 9 Dec 2013
Published: 20 Jan 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/53
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with three nitrogens as the only ring hetero…
A61K 9/0075
Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy: for inhalation via a dry…
A61K 31/166
Having aromatic rings, e.g. colchicine, atenolol, progabide: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g.…
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…

Family

Application61/913,744Us provisional application · filed 9 Dec 2013
Application61/913,734Us provisional application · filed 9 Dec 2013
Application15/102,957Continuation · filed 9 Jun 2016
Application17/211,071Continuation
US 11,911,390 B2Related patent
US 2016/0317542 A1Published application
US 2022/0016126 A1This patent

From the US filing history. Foreign family members aren’t listed.